Showing 1 - 10 of 29
Background:Background: The high number of patients with acute myocardial infarction (AMI) has facilitated greater research, resulting in the development of innovative medical devices. So far, results from economic evaluations that compared drug-eluting stents (DES) and bare-metal stents (BMS)...
Persistent link: https://www.econbiz.de/10011005060
Background:Background: Pulmonary arterial hypertension (PAH) is considered an orphan disease. Prostacyclins are the keystone for PAH treatment. Choosing between the three available prostacyclin therapies could be complicated because there are no comparison studies, so the final decision must be...
Persistent link: https://www.econbiz.de/10011005061
Background:Background: In spite of the important progress made in the abortive treatment of acute migraine episodes since the introduction of triptans, reduction of pain and associated symptoms is in many cases still not as effective nor as fast as would be desirable. Recent research pays more...
Persistent link: https://www.econbiz.de/10011005063
Background:Background: Vertebral compression fractures (VCFs) can be treated by nonsurgical management or by minimally invasive surgical treatment including vertebroplasty and balloon kyphoplasty. Abstract: Objective:Objective: The purpose of the present study was to characterize the cost to...
Persistent link: https://www.econbiz.de/10010552618
Background: Evidence about how people value health gains for different age groups is controversial and incomplete, despite the significance of this issue for priority setting in health policy. Objective: The aim of this study was to collect and analyse nationally representative data in the US...
Persistent link: https://www.econbiz.de/10010614265
The debate surrounding whether the findings of efficacy studies are applicable to real-world treatment situations is ongoing. The issue of lack of applicability due to a lack of clinical heterogeneity could be addressed by employing less restrictive inclusion criteria. Given that health economic...
Persistent link: https://www.econbiz.de/10010614269
Background: The Food and Drug Administration Modernization Act (FDAMA) of 1997, Best Pharmaceuticals for Children Act (BPCA) of 2002 and Pediatric Research Equity Act of 2007 provide an extended period of 6 months of marketing exclusivity (i.e. patent extension) to prescription drug...
Persistent link: https://www.econbiz.de/10010614273
Background: Previous research to develop a new generic paediatric health-related quality of life (HR-QOL) measure generated 11 dimensions of HR-QOL, covering physical, emotional and social functioning. These dimensions and their response scales were developed from interviews with children. Some...
Persistent link: https://www.econbiz.de/10010614279
The economic burden associated with osteoporosis is considerable. As such, cost-effectiveness analyses are important contributors to the diagnostic and therapeutic decision-making process. The aim of this study was to review the cost effectiveness of treating post-menopausal osteoporosis with...
Persistent link: https://www.econbiz.de/10010614280
Background: In virologically suppressed patients, switching to darunavir/ritonavir (DRV/r) monotherapy maintains HIV RNA suppression, and could also lower treatment costs. Objective: The purpose of this analysis was to calculate the potential cost savings from the use of DRV/r monotherapy in the...
Persistent link: https://www.econbiz.de/10010614281